Welcome to our dedicated page for Pressure Bio news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on Pressure Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pressure Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pressure Bio's position in the market.
Pressure BioSciences, Inc. (OTCQB: PBIO) has announced the award of its second U.S. patent for its Ultra Shear Technology (UST) platform, increasing its intellectual property to seven UST patents worldwide. This new patent, which focuses on a compact valve with throttling capability, enhances the production of stable nanoemulsions, potentially transforming numerous industries such as pharmaceuticals, food, and cosmetics. The UST platform promises improved bioavailability, quality, and operational efficiency, aiming for strong sales growth and profitability in 2022.
Pressure BioSciences, Inc. (OTCQB: PBIO) announced a strategic expansion of its patented BaroFold technology platform, addressing challenges in the protein therapeutics market expected to reach $233 billion by 2027. The BaroFold platform offers a cost-effective solution to protein aggregation and misfolding issues, enhancing production efficiency. Over two years, PBI's BaroFold Services business has grown from one customer to four, serving both startups and multi-billion-dollar companies. The scalable technology improves processing yields and reduces time to market for protein-based therapeutics, presenting lucrative opportunities for the company.
Pressure BioSciences, Inc. (PBIO) will participate in Benzinga's ALL ACCESS Investor Event on November 4, 2021, at 11:20 am ET. CEO Richard T. Schumacher will present in a unique format that blends interviews with presentations. The company announced strong financial growth in recent quarters and expects further improvement for Q3/Q4 2021, alongside plans to acquire an eco-friendly agrochemical supplier. Recent innovations include a patented UST platform yielding stable products and collaborations with Ohio State University for the food industry.
Pressure BioSciences (OTCQB: PBIO) has successfully utilized its Ultra Shear Technology (UST) platform to create stable, water-miscible concentrates of neem oil, positioning itself in the eco-friendly pesticide market. These nanoemulsions not only maintain efficacy over time but also offer a consistent application, addressing concerns with traditional neem oil products. The estimated annual cost of invasive insect damage is $70 billion globally, and the use of neem oil is expected to reduce agricultural losses. PBI is exploring commercialization opportunities via its new subsidiary, PBI Agrochem.
Pressure BioSciences, Inc. (PBIO) announced plans for establishing demonstration and toll manufacturing sites on the U.S. East and West Coasts to enhance its Ultra Shear Technology (UST) applications for nanoemulsions. The company is in discussions with partners to accelerate product demonstrations and fulfill growing manufacturing demands, particularly from sectors like pharmaceuticals and nutraceuticals. Early feedback indicates significant interest in UST's capabilities, especially for hemp-derived products. PBIO aims to launch its UST systems by late 2021 or early 2022, targeting profitability by late 2022.
Pressure BioSciences, Inc. (OTCQB:PBIO) is set to present at the Benzinga Healthcare and Emerging Growth Small Cap Conferences. CEO Richard T. Schumacher will discuss the company's revenue growth in 2021, the anticipated commercial release of its Ultra Shear Technology™ platform, and its acquisition of eco-friendly agrochemical assets. The Emerging Growth Conference is on September 29, 2021, and the Benzinga Healthcare Conference is on September 30, 2021. PBI focuses on pressure-based solutions for various industries and aims to up-list to a national stock exchange.
Pressure BioSciences (PBIO) reported robust Q2 2021 financial results, with total revenue skyrocketing by 127% to $608,900, driven by a 178% rise in instrument sales. BaroFold/UST services surged 298%. The operating loss reduced by 51% to $646,300, improving net loss per share to $(0.90). For the first half, total revenue increased 124% to $1,168,800. The formation of PBI Agrochem is expected to unlock further growth, with over $1,000,000 in orders received in its first month. A positive outlook for Q3 and Q4 2021 is anticipated.
Pressure BioSciences, Inc. (PBIO) will hold a teleconference on August 19, 2021, at 4:30 PM ET to discuss its Q2 2021 financial results and ongoing business activities. The call will feature a presentation followed by a Q&A session. Interested parties can join via telephone or listen to a replay available after August 20, 2021. PBIO aims to leverage its pressure cycling technology for various applications, including biopharma contract services and food preservation, enhancing its market presence significantly.
Pressure BioSciences (OTCQB:PBIO) announced the successful launch of its eco-friendly agrochemical subsidiary, PBI Agrochem, Inc., which garnered over $1,000,000 in purchase orders in its first month. CEO Richard T. Schumacher will present at the Emerging Growth Conference on August 18, 2021, providing insights on this achievement and the company's strategy. The initial orders are expected to ship in Q3 2021, with the expectation of significant recurring revenue and profitability by 2022.
Pressure BioSciences (OTCQB: PBIO) has established its new agrochemicals subsidiary, PBI Agrochem, which has secured over $1M in initial purchase orders for eco-friendly agrochemical products. This initiative is expected to significantly enhance Q3 2021 revenues. The company plans to integrate PBI Agrochem into the supply chain of a planned acquisition of a global agrochemicals business, aiming for a major growth trajectory. PBI's management anticipates that strong early sales will lead to a potential doubling of quarterly revenues, paving the way towards profitability by the end of 2022.